Detection times of pregabalin in urine after illicit use: When should a positive specimen be considered a new intake?

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 137-140

  Spigset, Olav ^a,b   Westin, Andreas A ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

drugs of abuse; pharmacokinetics; pregabalin; renal function; urinary analysis

Indexed keywords

CREATININE; PICRIC ACID; PREGABALIN;

ARTICLE; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG ABUSE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SCREENING; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; HUMANS; MALE; SUBSTANCE ABUSE DETECTION;

EID: 84872834649     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827789dd     Document Type: Article

References (19)

1. Verstraete AG. Detection times of drug of abuse in blood, urine and oral fluid. Ther Drug Monit. 2004;26:200-205.
2. Lennestål R, Lakso H-Å, Nilsson M, et al. Urine monitoring of diazepam abuse - new intake or not? J Anal Toxicol. 2008;32:402-407.
3. Huestis MS, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol. 1998;22:445-454.
4. Sills GJ. The mechanism of action of gabapentin and pregabalin. Curr Opin Pharmacother. 2006;6:108-113.
5. European Medicines Agency. Lyrica-summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000546/WC500046602.pdf. Accessed July 2, 2012.
6. U.S. Food and Drug Administration. Label approved on August 24, 2011, for Lyrica. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022488-s004-0211446s025lbl.pdf. Accessed July 2, 2012.
7. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661-669.
8. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.
9. Schwan S, Sundström A, Stjernberg E, et al. A signal for an abuse liability for pregabalin - results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-953.
10. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110: 605-607.
11. Schifano F, D'Offizsi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118-122.
12. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005;70:43633-43635.
13. European Medicines Agency (EMA). Lyrica. Procedural steps taken after authorisation. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Procedural-steps-taken-and-scientific-information-after- authorisation/human/000546/WC500046604.pdf. Accessed July 2, 2012.
14. Heltsley R, DePriest A, Black Dl, et al. Urine drug testing of chronic pain patients. IV. Prevalence of gabapentin and pregabalin. J Anal Toxicol. 2011;35:357-359.
15. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43:277-283.
16. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50: 941-950.
17. Bockbrader HN, Burger P, Knapp L, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52:248-257.
18. Shoji S, Suzuki M, Tomono Y, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol. 2011;72:63-76.
19. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.